Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 321

1.

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V.

J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46. Review. Erratum in: J Natl Cancer Inst 2000 Feb 2;92(3):275.

PMID:
10547390
2.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
3.

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.

Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.

PMID:
12093250
5.

Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?

Taylor AL, Adams-Campbell LL, Wright JT Jr.

J Natl Cancer Inst. 1999 Nov 3;91(21):1792-3. No abstract available.

PMID:
10547378
6.

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH.

J Natl Cancer Inst. 2003 Apr 2;95(7):526-32.

PMID:
12671020
7.

Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective.

Goldhaber SZ.

Circulation. 2005 Feb 8;111(5):539-41. No abstract available.

8.

Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.

Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U; Italian Tamoxifen Study Group.

Circulation. 2005 Feb 8;111(5):650-6.

9.

Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.

Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S.

Cancer. 2005 May 15;103(10):1996-2005.

10.

Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Love RR.

J Natl Cancer Inst. 1999 Nov 3;91(21):1891-2. No abstract available.

PMID:
10547398
11.

Chemoprevention of breast cancer.

Dalton RR, Kallab AM.

South Med J. 2001 Jan;94(1):7-15. Review.

PMID:
11213947
12.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
13.

Chemoprevention for high-risk women: tamoxifen and beyond.

Fabian CJ, Kimler BF.

Breast J. 2001 Sep-Oct;7(5):311-20. Review.

PMID:
11906441
14.

Chemoprevention of breast cancer in the older patient.

Minton SE.

Hematol Oncol Clin North Am. 2000 Feb;14(1):113-30. Review.

PMID:
10680075
15.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
16.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ.

Oncologist. 2004;9(2):116-25. Review.

17.

The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N.

Clin Breast Cancer. 2002 Jun;3(2):153-9.

PMID:
12123540
18.

Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.

Brewster AM, Christo DK, Lai H, Helzlsouer K.

Cancer. 2005 Mar 15;103(6):1147-53.

19.

Breast cancer prevention with selective estrogen receptor modulators: a perspective.

Pritchard KI.

Ann N Y Acad Sci. 2001 Dec;949:89-98. Review.

PMID:
11795385
20.

Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.

Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer Study Group.

J Natl Cancer Inst. 2005 Mar 2;97(5):375-84.

PMID:
15741574

Supplemental Content

Support Center